HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Stocks · News reference
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.